<DOC>
	<DOCNO>NCT01468376</DOCNO>
	<brief_summary>The purpose study determine safe , tolerable efficacious dose GLU-xx .</brief_summary>
	<brief_title>GLU-xx Formulations Individuals With Impaired Glucose Tolerance</brief_title>
	<detailed_description />
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>Generally healthy adult 2165 year age Body Mass Index ( BMI ) 25 ≤40 OGTT ( 75g glucola ) peak value ≥140mg/dl ≤199 mg/dl screen visit Willingness adhere requirement protocol , include availability followup visit donation blood sample Willingness ability sign write informed consent Women child bearing capacity agree use acceptable form birth control trial [ i.e. , oral contraception , reliable use doublebarrier method ( e.g. , condom diaphragm , condom foam , condom sponge ) , IUD tubal ligation ] Active diabetes mellitus [ fast blood glucose ≥7.0 mmol/L ( ≥126 mg/dL ) ≥11.1 mmol/L ( ≥200 mg/dL ) OGTT ] Current coronary artery/ cardiovascular disease history cardiovascular event ( stroke , transient ischemic attack , myocardial infarction , angioplasty coronary artery bypass grafting , angina pectoris ) undergone cardiovascular intervention within past three month Seizure disorder Blood disorder , include anemia ( i.e. , hemoglobin level less 13 g/dL men le 12 g/dL woman ) Active infection , include HIV , hepatitis , etc Participants Estrogen replacement must stable dose least 3 month Serious illness require ongoing medical care medication Gastrointestinal disorder prior gastrointestinal surgery ( include gastric bypass lapband ) might cause complication influence motility satiety ( e.g. , diverticulitis , inflammatory bowel disease , irritable bowel syndrome , intestinal narrowing obstruction , difficulty swallow ) Any congenital spinal cord deformities traumatic spinal cord injury Uncorrected hypothyroidism Other significant metabolic endocrine disease Active liver disease liver function impairment evidence history liver disease liver enzyme elevation &gt; three time upper limit normal Current cancer Significant kidney disease ( calculate eGFR &lt; 60 mL/min ) History clinical manifestation significant metabolic , hepatic , renal , hematological , pulmonary , cardiovascular , gastrointestinal , urological , neurological , psychiatric disorder opinion investigator would expect interfere study increase risk subject Use anticoagulant warfarin Use medication might affect weight food absorption ( e.g. , diuretic , glucocorticoid , anorexigenic agent , Orlistat , laxatives ) Treatment within previous 6 month medication know affect glucose level ( insulin without amylin analogue , sulfonylurea , meglitinides , biguanide metformin , thiazolidinediones , alphaglucosidase inhibitor , oral dipeptidylpeptidase4 inhibitor , Sitagliptin , Incretin mimetic ) Regular use natural health product dietary supplement know affect glucose level ( chromium , zinc , fenugreek , cinnamon ) . If participant agree stop take product 14 day prior study entry duration study , participate study Any natural health product dietary supplement , exception vitamin mineral dose &lt; 600 mg/day vitamin E contain vitamin K. Natural health product dietary supplement include product , limited , Echinacea , Ginseng , St. John 's Wort , Gingko , Glucosamine , Fish Oil supplement , Evening Primrose Oil , Green Tea herbal product consume form pill , extract , capsule , tablet . If participant agree stop take product 14 day prior study entry duration study , participate study Vegan Vegetarian Pregnant lactate woman , intend become pregnant Known allergy ingredient study product Any significant autoimmune disease</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>impaired glucose tolerance</keyword>
	<keyword>pre-diabetes</keyword>
</DOC>